{"name":"Instil Bio","slug":"instil","ticker":"TIL","exchange":"NASDAQ","domain":"instilbio.com","description":"Instil Bio is a biotechnology company focused on developing cell therapies for the treatment of cancer. The company's lead product, TIL-110, is an autologous tumor-infiltrating lymphocyte (TIL) therapy for the treatment of solid tumors. Instil Bio has a strong pipeline of cell therapy products in various stages of development, with a focus on immuno-oncology. The company is positioned to capitalize on the growing demand for cell therapies in the oncology market.","hq":"Dallas, TX","founded":0,"employees":"","ceo":"Bronson Crouch","sector":"Cell Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":1000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":39604000,"netIncome":-71372000,"cash":6638000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Instil Bio Announces FDA Clearance of IND for TIL-110","summary":"Instil Bio announced that the FDA has cleared the Investigational New Drug (IND) application for TIL-110, enabling the company to initiate a Phase 1 clinical trial.","drugName":"TIL-110","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Instil Bio Reports Third Quarter 2023 Financial Results","summary":"Instil Bio reported its third quarter 2023 financial results, with a net loss of $24.4 million and a cash balance of $143.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOZkFhc1FRWVhFV19HQ3QwZ1ltN3Nhc3pHUmtFVGd0dmFkLU1iQXdnT2hWMGNmTmVTMDROcW5Sa2FxVzAzcGttbGwwWTN1SUVkR1M2b0dPckRiams5al9SMWJSR2UwWTlxMGJuVHMxV0t0Yno1U0k5SmQ5dTgzX25Veg?oc=5","date":"2026-04-06","type":"pipeline","source":"MarketBeat","summary":"Top Curanex Pharmaceuticals (CURX) Competitors 2026 - MarketBeat","headline":"Top Curanex Pharmaceuticals (CURX) Competitors 2026","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNQ1Vydl9YS25jOUhEVHRLaU1INHZrMDhPU3pDWGJDOW8tVURMMkZoRXdER05ld0NvNGxSQkhYUWdkZEFSaFNiZXRSd2daSC16X3VtcE1tbXgwSnZ1ZW0xejNodlI1OUZoUHlEeU9Na19seHBQSDFfUy1FeTFXaVFNU2Jqejl1XzRoaGtBY0hhaEFTWVJTUzMxWVJKeWg2T2RKLXF0RkhySE5wODhyYWFRT2p1TVAzRzQzNS10MUFYcFNTbVpq?oc=5","date":"2026-01-06","type":"pipeline","source":"Fierce Biotech","summary":"Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco - Fierce Biotech","headline":"Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-26","type":"earnings","source":"simplywall.st","summary":"Institutional owners may ignore Instil Bio, Inc.'s (NASDAQ:TIL) recent US$21m market cap decline as longer-term profits stay in the green - simplywall.st","headline":"Institutional owners may ignore Instil Bio, Inc.'s (NASDAQ:TIL) recent US$21m market cap decline as longer-term profits ","sentiment":"negative"},{"date":"2025-08-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-07-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOT3dHTFFWaEZmVHJfZFhvR0VJQkZVd3FjcDNpSW9JczkwSW45X3p5UExhczFvRmlobFU0cjY5ZlVuSGRqUGhsSkw2aUg4R0NyTTU0Y1ZBQXJzc3ZSa05ySlg1RWhNNXZxNndmMUN5TjBaQm1VdUtPODJVTWhnYXFTSUIzb280aXpTc3d0djNtRHhZOEw0cU9ocjA5RE9Nd0NhRkl3N2Jnelg1MFBzbWJDMXdQbFJqT0JNWWc?oc=5","date":"2025-06-04","type":"deal","source":"Moomoo","summary":"Investing in Biotech? Why China Partnerships Are a Game Changer - Moomoo","headline":"Investing in Biotech? Why China Partnerships Are a Game Changer","sentiment":"neutral"},{"date":"2025-05-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-05-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Cell Therapy","Immuno-Oncology"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":0,"period":"2021-12-31"},{"value":138000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":39604000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-71372000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":6638000,"cashHistory":[],"totalAssets":203523000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}